HCmed Innovations Co., Inc., a drug-device combination company focused on inhalation therapy, presented its latest brand, Pulmogine, in the 2019 ERS International Congress.

今(22)日，心誠鎂行動醫電宣布，將於今年第三季正式推出新品牌Pulmogine，以霧化高價值之治療藥物為主，種類包含懸浮液劑型、高黏滯係數、抗生素、生物製劑以及脂質體藥物。

Handheld nebulizer manufacturer HCmed Innovations announced that it has accepted an invitation to build an R&D center and production facility in the newly opened Wuxi International Life Science Innovation Park, which is anchored by AstraZeneca.

HCmed Innovations joins Wuxi International Life Science Innovation Park supported by AstraZeneca China

無錫國際生命科學創新園區正式開園心誠鎂為臺灣唯一受邀進駐(左起為心誠鎂董事長鄭傑升、阿斯特捷利康全球執行副總裁王磊).